Solvay is a Belgian, chemical and pharmaceutical company with headquarter in Brussels. They possess establishments over 50 countries, all over the world. Solvay produces several products for all kinds of pharmaceutical levels like drugs for cholesterol, Parkinson, …
After a 5 month long decision period, Abbott Laboratories decided to take over Solvay Pharmaceutical. The merger will invest €4.5bn into Solvay Pharmaceutical. So, they can strengthen their position on the pharmaceutical market. Because of Abbott’s strategic decision, they beated UCB of Belgium and Nycomed of Switzerland. Nycomed made an offer of €4bn. Due to this offer, they raised their debts about €2bn to finance it. Just like Nycomed, UCB offered €4bn, in the hope to become Belgian’s most important pharmaceutical company.
We think this takeover is a good decision of Abbott because the pharmaceutical market is rentable sector which grows year after year. Somewhere we regret that UCB failed to take over Solvay. Otherwise Belgium could accomplish a stronger position in the pharmaceutical sector. The main question is: “ What will Solvay do with all this money?!” We encourage Solvay to do (more) research on life-threatened diseases. So that they can discover remedies and help (more) people in need. The research will lead into 2 positive directions: Abbott will be able to increase their profit and they can also create a hopeful position for sick people.
Posted by: Ruth Blommaert, Sofie De Cooman, Steffie De Ridder, Joachim De Zutter and Elise Van Praet.
SOURCE: http://www.ft.com/cms/s/0/11d12820-ab7b-11de-9be4-00144feabdc0.html?nclick_check=1
After a 5 month long decision period, Abbott Laboratories decided to take over Solvay Pharmaceutical. The merger will invest €4.5bn into Solvay Pharmaceutical. So, they can strengthen their position on the pharmaceutical market. Because of Abbott’s strategic decision, they beated UCB of Belgium and Nycomed of Switzerland. Nycomed made an offer of €4bn. Due to this offer, they raised their debts about €2bn to finance it. Just like Nycomed, UCB offered €4bn, in the hope to become Belgian’s most important pharmaceutical company.
We think this takeover is a good decision of Abbott because the pharmaceutical market is rentable sector which grows year after year. Somewhere we regret that UCB failed to take over Solvay. Otherwise Belgium could accomplish a stronger position in the pharmaceutical sector. The main question is: “ What will Solvay do with all this money?!” We encourage Solvay to do (more) research on life-threatened diseases. So that they can discover remedies and help (more) people in need. The research will lead into 2 positive directions: Abbott will be able to increase their profit and they can also create a hopeful position for sick people.
Posted by: Ruth Blommaert, Sofie De Cooman, Steffie De Ridder, Joachim De Zutter and Elise Van Praet.
SOURCE: http://www.ft.com/cms/s/0/11d12820-ab7b-11de-9be4-00144feabdc0.html?nclick_check=1
According to us this is a good decision of Abbott because now they have a better position on the market. Abbott can deliver products to a larger range of people. Starting today Abbott can make profit out of Solvay's good name. This is also a good decision for the pharmaceutical sector in its whole, because now they can do more research and development.
BeantwoordenVerwijderenGroup: Kirsten, Charlotte, Tom and Maxime (international trade 3FV1)